CLPT Valuation
Clearpoint Neuro Inc
$
12.130
- Overview
- Forecast
- Valuation
CLPT Relative Valuation
CLPT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CLPT is overvalued; if below, it's undervalued.
Historical Valuation
No Data
Competitors Valuation Multiple
The average P/S ratio for CLPT's competitors is 4.85, providing a benchmark for relative valuation. Clearpoint Neuro Inc Corp (CLPT) exhibits a P/S ratio of 8.54, which is 76.13% above the industry average. Given its robust revenue growth of 11.07%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
KALV
Kalvista Pharmaceuticals Inc
11.810
USD
-3.51%
OTLY
Oatly Group AB (publ)
10.020
USD
-2.34%
KMDA
Kamada Ltd
6.940
USD
+1.02%
OFLX
Omega Flex Inc
34.075
USD
+0.07%
HYLN
Hyliion Holdings Corp
1.259
USD
-0.08%
PKST
Peakstone Realty Trust
11.980
USD
-2.60%
OBE
Obsidian Energy Ltd
4.790
USD
+0.84%
SPMC
Sound Point Meridian Capital Inc
18.220
USD
-0.27%
PSNL
Personalis Inc
4.790
USD
-3.43%
DGICA
Donegal Group Inc
20.310
USD
-1.46%
FAQ
Is Clearpoint Neuro Inc (CLPT) currently overvalued or undervalued?
Clearpoint Neuro Inc (CLPT) is now in the Fair zone, suggesting that its current forward PS ratio of 8.54 is considered Fairly compared with the five-year average of 11.03. The fair price of Clearpoint Neuro Inc (CLPT) is between 7.21 to 21.65 according to relative valuation methord.
What is Clearpoint Neuro Inc (CLPT) fair value?
How does CLPT's valuation metrics compare to the industry average?
What is the current P/B ratio for Clearpoint Neuro Inc (CLPT) as of May 21 2025?
What is the current FCF Yield for Clearpoint Neuro Inc (CLPT) as of May 21 2025?
What is the current Forward P/E ratio for Clearpoint Neuro Inc (CLPT) as of May 21 2025?